Generation and characterization of IgG monoclonal antibodies specific for malondialdehyde

Hybridoma and Hybridomics

Volumn 22, Issue 4, 2003, Pages 259-262

  Choi, Ji Woong ^a   Kim, Dong Jo ^a   Rhim, Jung Hyo ^a   Chung, Jun Ho ^a,b   Chung, Hong Keun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MDA1; MONOCLONAL ANTIBODY MDA2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; LIPID OXIDATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; WILD TYPE;

ANIMALIA; MURINAE;

EID: 0041836050     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685903322328983     Document Type: Article

References (16)

1. Goldstein JL, and Brown MS: The low-density lipoprotein pathway and its relation to atherosclerosis. Annu Rev Biochem 1977;46:897-903.
2. Esterbauer H, Dieber-Rotheneder M, Waeg G, Striegl G, and Jurgens G: Biochemical, structural, and functional properties of oxidized low-density lipoprotein. Chem Res Toxicol 1990;3:77-92.
3. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
4. Wick G, Schett G, Amberger A, Kleindienst R, and Xu Q: Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16:27-33.
5. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, and Wiklund O: Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998;18:1203-1211.
6. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, Chen PP, and Wiztum JL: Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001;21:1333-1339.
7. Slatter DA, Murray M, and Bailey AJ: Formation of a dihydropyridine derivative as a potential cross-link derived from malondialdehyde in physiological systems. FEBS Lett 1998;421:180-184.
8. Chung HK, Kim SS, and Suh PG: Development and evaluation of two site binding radioimmunoassay for human alpha fetoprotein using monoclonal antibodies. Korean J Biochem 1984;16:97-103.
9. Lee HS, and Koh HI: Visualization of binding and uptake of oxidized low-density lipoproteins by cultured mesangial cell. Lab Invest 1994;71:200-208.
10. Goldstein JL, Ho YK, Basu SK, and Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low-density lipoprotein producing massive cholesterol derposition. Proc Natl Acad Sci USA 1979;76:333-337.
11. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E: Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993;4:1119-1122.
12. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93:229-240.
13. Hörkkö S, Binder CJ, Shaw PX, Chang MK, Silverman G, Palinski W, Witztum JL: Immunological responses to oxidized LDL. Free Radic Biol Med 2000;28:1771-1779.
14. Schmitt A, Negre-Salvayre A, Troly M, Valdiguie P, Salvayre R: Phospholipid hydrolysis of mildly oxidized LDL reduces their cytotoxicity to cultured endothelial cells. Potential protective role against atherogenesis. Biochim Biophys Acta 1995;1256:284-292.
15. Mertens A, Holvoet P: Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001;15:2073-2084.
16. Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K, Takahashi K, Kanno T, Saito Y: Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol 2002;22:662-666.